Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2019

01-12-2019 | Sarcoma | Sarcoma

Is Peritoneal Tumor Penetration of Prognostic Importance in Gastrointestinal Stromal Tumors?

Authors: T. Hølmebakk, MD, B. Bjerkehagen, MD, PhD, I. V. K. Lobmaier, MD, I. Hompland, MD, PhD, S. Stoldt, MD, K. Boye, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2019

Login to get access

Abstract

Background

Peritoneal tumor penetration (PP) strongly affects prognosis in gastrointestinal carcinomas. In gastrointestinal stromal tumor (GIST), its significance in the absence of tumor rupture has not been subjected to detailed analysis.

Methods

Patients undergoing complete resection for non-metastatic GIST from 2000 to 2017 were identified in the regional sarcoma database at Oslo University Hospital. Patients with extraperitoneal tumors (esophagus, rectum) or ruptured tumors were excluded from the study. Rupture was defined according to the Oslo criteria, and PP was assessed via routine histopathologic examination by sarcoma pathologists.

Results

The study enrolled 341 patients. The median follow-up period was 51 months (range 0–175) months. In 82 (24%) of the 341 patients, PP was recorded. There were 32 recurrences, 9 in patients with PP and 23 in patients without PP. Despite statistically significant associations between PP and established risk factors (size, mitotic index, non-gastric location), the 5-year recurrence-free survival rate did not differ between the patients with PP (86%) and those without PP (90%) (hazard ratio 1.25; 95% confidence interval 0.582.70; P = 0.577). Adjuvant imatinib was administered to 53 of 97 patients in the high-risk category. The recurrence rates did not differ between the PP-positive and PP-negative patients in either group.

Conclusions

In GIST, PP without tumor rupture appears not to influence prognosis. This lack of prognostic significance may reflect unexplored differences between epithelial and mesenchymal malignancies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992;1:341–6.CrossRef Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992;1:341–6.CrossRef
2.
go back to reference Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, De Stefano A, Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRef Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, De Stefano A, Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113–9.CrossRef
3.
go back to reference O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:420–5. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:420–5.
4.
go back to reference Gunderson LI, Jessup JM, Sargent DJ, Greene FI, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;2:264–71.CrossRef Gunderson LI, Jessup JM, Sargent DJ, Greene FI, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;2:264–71.CrossRef
5.
go back to reference Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRef Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.CrossRef
6.
go back to reference Miettinen M, Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMed Miettinen M, Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMed
7.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumour. Hum Pathol. 2008;39:1411–9.CrossRef Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumour. Hum Pathol. 2008;39:1411–9.CrossRef
8.
go back to reference Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.CrossRef Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.CrossRef
9.
go back to reference Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.CrossRef Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–74.CrossRef
10.
go back to reference Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM classification of malignant tumours (UICC). 8th ed. Oxford: Wiley; 2017. Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM classification of malignant tumours (UICC). 8th ed. Oxford: Wiley; 2017.
11.
go back to reference Hølmebakk T, Bjerkehagen B, Boye K, Bruland O, Stoldt S, Sundby Hall K. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg. 2016;103:684–91.CrossRef Hølmebakk T, Bjerkehagen B, Boye K, Bruland O, Stoldt S, Sundby Hall K. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg. 2016;103:684–91.CrossRef
12.
go back to reference Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol. 2018;25:1133–9.CrossRef Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol. 2018;25:1133–9.CrossRef
13.
go back to reference Bischof DA, Kim Y, Dodson R, et al. Conditional disease-free survival after surgical resection of gastrointestinal stromal tumours. JAMA Surg. 2015;150:299–306.CrossRef Bischof DA, Kim Y, Dodson R, et al. Conditional disease-free survival after surgical resection of gastrointestinal stromal tumours. JAMA Surg. 2015;150:299–306.CrossRef
14.
go back to reference Nishida T, Cho H, Hirota S, et al. Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world. Ann Surg Oncol. 2018;25:1961–9.CrossRef Nishida T, Cho H, Hirota S, et al. Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world. Ann Surg Oncol. 2018;25:1961–9.CrossRef
15.
go back to reference Hølmebakk T, Bjerkehagen B, Hompland I, Stoldt S, Boye K. Relationship between R1 resection, tumour rupture, and recurrence in resected gastrointestinal stromal tumour. Br J Surg. 2019;106:419–26.CrossRef Hølmebakk T, Bjerkehagen B, Hompland I, Stoldt S, Boye K. Relationship between R1 resection, tumour rupture, and recurrence in resected gastrointestinal stromal tumour. Br J Surg. 2019;106:419–26.CrossRef
16.
go back to reference Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumour. Ann Surg Oncol. 2007;14:2018–27.CrossRef Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumour. Ann Surg Oncol. 2007;14:2018–27.CrossRef
17.
go back to reference Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.CrossRef Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.CrossRef
18.
go back to reference Sano T, Coit DG, Kim HH, et al. Proposal of a new-stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project. Gastric Cancer. 2018;20:217–25.CrossRef Sano T, Coit DG, Kim HH, et al. Proposal of a new-stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project. Gastric Cancer. 2018;20:217–25.CrossRef
19.
go back to reference Soga K, Ichikawa D, Yasukawa S, et al. Prognostic impact of the width of subserosal invasion in gastric cancer invading the subserosal layer. Surgery. 2010;2:197–203.CrossRef Soga K, Ichikawa D, Yasukawa S, et al. Prognostic impact of the width of subserosal invasion in gastric cancer invading the subserosal layer. Surgery. 2010;2:197–203.CrossRef
20.
go back to reference Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively collected database. BMC Cancer. 2013;13:57.CrossRef Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively collected database. BMC Cancer. 2013;13:57.CrossRef
21.
go back to reference Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012;23:3123–9.CrossRef Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol. 2012;23:3123–9.CrossRef
22.
go back to reference Jayne D. Molecular biology of peritoneal carcinomatosis. In: Ceelen WP, editors. Peritoneal carcinomatosis. A multidisciplinary approach. New York: Springer; 2007. Jayne D. Molecular biology of peritoneal carcinomatosis. In: Ceelen WP, editors. Peritoneal carcinomatosis. A multidisciplinary approach. New York: Springer; 2007.
23.
go back to reference Yanagimoto Y, Takahashi T, Muguruma K, et al. Reappraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426–33.CrossRef Yanagimoto Y, Takahashi T, Muguruma K, et al. Reappraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18:426–33.CrossRef
Metadata
Title
Is Peritoneal Tumor Penetration of Prognostic Importance in Gastrointestinal Stromal Tumors?
Authors
T. Hølmebakk, MD
B. Bjerkehagen, MD, PhD
I. V. K. Lobmaier, MD
I. Hompland, MD, PhD
S. Stoldt, MD
K. Boye, MD, PhD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07813-x

Other articles of this Issue 13/2019

Annals of Surgical Oncology 13/2019 Go to the issue